The following article from Practice Update discusses the JAVELIN Renal 101 clinical trial, which compares avelumab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma (RCC). The article highlights the results of this particular trial and touches upon other combinations of vascular endothelial growth factor (VEGF) inhibitors with immunotherapy as having not just additive, but synergistic, effects for the treatment of advanced RCC. For example, VEGF inhibitors are thought to have some immune-related properties, such as increasing the movement of immune cells into tumours and decreasing the activity of immune suppressor cells allowing the immune system to be stimulated.
Results from JAVELIN Renal 101 clinical trial – avelumab plus axitinib combination for advanced kidney cancer
28 Nov 2018
avelumab
axitinib
Bavencio
checkpoint inhibitors
combination therapy
immunotherapy
Inlyta
renal cell carcinoma
sunitinib
Sutent
TKIs
VEGF inhibitors
Most used tags
renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo sunitinib Sutent progression-free survival cabozantinib biomarkers NHS England Cabometyx ipilimumab pembrolizumab COVID-19 cancer survival axitinib VEGF inhibitors non-clear cell kidney cancer Inlyta coronavirus Yervoy risk factors Keytruda metastases adjuvant therapy biological markers papillary RCC targeted therapy everolimus Afinitor ASCO cancer outcomes first-line treatment NICE partial nephrectomyArchives
- 2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec